Amedeo Smart

Free Medical Literature Service

 

Amedeo

Head and Neck Cancer
  Free Subscription

Articles published in
Clin Cancer Res
    June 2025
  1. SABA NF, Flamand Y, Lin DT, Chung CH, et al
    Neoadjuvant Chemotherapy and Surgery versus Surgery for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma: ECOG-ACRIN EA3163.
    Clin Cancer Res. 2025;31:2339-2346.
    >> Share

  2. TANG LQ, Liu SL, Yang MH, Wang HC, et al
    GFH018 and toripalimab combination therapy for previously treated recurrent or metastatic nasopharyngeal carcinoma: Results from a phase 1b/2 study.
    Clin Cancer Res. 2025 Jun 13. doi: 10.1158/1078-0432.CCR-25-0085.
    >> Share

    May 2025
  3. DHOLARIA H, Tsetlina V, Simpson SK, Gillies E, et al
    One-Two Punch: Combining Chemotherapy and Immunotherapy to Decrease Radiation Dose and Related Toxicity in Children and Adolescents with Nasopharyngeal Carcinoma.
    Clin Cancer Res. 2025 May 30. doi: 10.1158/1078-0432.CCR-24-3546.
    >> Share

  4. BRYAN ME, Aye L, Das D, Hirayama S, et al
    Direct Comparison of Alternative Blood-Based Approaches for Early Detection and Diagnosis of HPV-Associated Head and Neck Cancers.
    Clin Cancer Res. 2025 May 20:OF1-OF11. doi: 10.1158/1078-0432.CCR-24-2525.
    >> Share

  5. SIM ES, Rhoades J, Xiong K, Walsh L, et al
    Early Postoperative Minimal Residual Disease Detection with MAESTRO Is Associated with Recurrence and Worse Survival in Patients with Head and Neck Cancer.
    Clin Cancer Res. 2025 May 20:OF1-OF9. doi: 10.1158/1078-0432.CCR-25-0307.
    >> Share

  6. CAO X, Luo ZY, Huang HY, Zhou JY, et al
    Capecitabine maintenance therapy in patients with residual nasopharyngeal carcinoma: a single-arm, phase 2 trial.
    Clin Cancer Res. 2025 May 19. doi: 10.1158/1078-0432.CCR-24-4132.
    >> Share

  7. ZHANG W, Li JB, Liu HM, Wang KM, et al
    PERK+ Macrophages Drive Immunotherapy Resistance in Lymph Node Metastases of Oral Squamous Cell Carcinoma.
    Clin Cancer Res. 2025;31:1894-1911.
    >> Share

  8. SCHMITT NC, Stokes WA, Bates JE, Kinney BLC, et al
    Early-phase trial of IAP antagonist tolinapant and definitive radiation in cisplatin-ineligible patients with advanced head and neck cancer.
    Clin Cancer Res. 2025 May 12. doi: 10.1158/1078-0432.CCR-25-0429.
    >> Share

  9. CALIFANO JA
    So Close, and Yet... Plasma HPV DNA Detection of Recurrent HPV Oropharynx Cancer.
    Clin Cancer Res. 2025;31:1561-1562.
    >> Share

  10. QIAN Y, Tang L, Yao J, Zhu Y, et al
    Pembrolizumab with Chemotherapy for Patients with Recurrent or Metastatic Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma: A Prospective Phase ll Study.
    Clin Cancer Res. 2025;31:1636-1643.
    >> Share

  11. BARTEMES KR, Moore RM, Novotny BC, Pavelko KD, et al
    Increased Interaction between B Cells and CD3+ T Cells in Nonprogressors with Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.
    Clin Cancer Res. 2025;31:1719-1729.
    >> Share

  12. RETTIG EM, Schoenfeld JD, Miller J, Sargent B, et al
    A Prospective Trial of Biomarker-Guided Surveillance for HPV-Positive Oropharynx Cancer Using Plasma Tumor Tissue-Modified Viral HPV DNA.
    Clin Cancer Res. 2025;31:1605-1614.
    >> Share

  13. GUAN L, Torres-Saavedra PA, Zhao X, Major MB, et al
    Association between Locoregional Failure and NFE2L2/KEAP1/CUL3 Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer.
    Clin Cancer Res. 2025;31:1615-1624.
    >> Share

  14. PEREZ-PACHECO CG, Gonzalez-Maldonado LA, Furgal A, Schmitd LB, et al
    Nerve Types and Classification of Neurons Innervating Oral Cancer.
    Clin Cancer Res. 2025 May 1. doi: 10.1158/1078-0432.CCR-24-2375.
    >> Share

    April 2025
  15. FAYETTE J, Licitra L, Harrington K, Haddad R, et al
    INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab Plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2025 Apr 29. doi: 10.1158/1078-0432.CCR-25-0073.
    >> Share

  16. WALCH HS, Borpatragohain R, Jee J, Chatila W, et al
    Clinical Implications of The Cancer Genome Atlas Molecular Classification System in Esophagogastric Cancer.
    Clin Cancer Res. 2025 Apr 29:OF1-OF10. doi: 10.1158/1078-0432.CCR-24-3473.
    >> Share

    March 2025
  17. MCCOON P, Wang Y, Lai Z, Zhang Q, et al
    Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor Outcome.
    Clin Cancer Res. 2025 Mar 13. doi: 10.1158/1078-0432.CCR-24-2198.
    >> Share

  18. LEE J, Shin Y, Kwak J, Park HL, et al
    Validation of Diagnostic Utility of Washout CYFRA 21-1 in Lymph Node Metastasis of Thyroid Cancer.
    Clin Cancer Res. 2025 Mar 12. doi: 10.1158/1078-0432.CCR-24-3562.
    >> Share

  19. TSENG I, Chen Y, Ai D, Zhu Z, et al
    Radiation Dose-Volume Effects on Negative Tumor-Draining Lymph Nodes Impacted T-Cell Activation and Prognosis in Esophageal Cancer with Chemoradiotherapy.
    Clin Cancer Res. 2025 Mar 7. doi: 10.1158/1078-0432.CCR-24-4123.
    >> Share

  20. COLEVAS AD, Talebi Z, Winters E, Even C, et al
    First-in-Human Clinical Trial of a Small-Molecule EBNA1 Inhibitor, VK-2019, in Patients with Epstein-Barr-Positive Nasopharyngeal Cancer, with Pharmacokinetic and Pharmacodynamic Studies.
    Clin Cancer Res. 2025;31:815-823.
    >> Share

    February 2025
  21. RAO YJ
    Biomarkers of radioresistance in head and neck cancer: a new beginning.
    Clin Cancer Res. 2025 Feb 18. doi: 10.1158/1078-0432.CCR-24-4223.
    >> Share

  22. WANG C, Niu X, Xia T, Wang P, et al
    Predicting c-KIT Inhibitor Efficacy in Patient-Derived Models of Sinonasal Mucosal Melanomas through Integrated Histogram Analysis of Whole-Tumor DKI, IVIM, and DCE-MRI.
    Clin Cancer Res. 2025 Feb 12. doi: 10.1158/1078-0432.CCR-24-3765.
    >> Share

    January 2025
  23. CONTRERA KJ, Ferrarotto R, Gunn B, Su SY, et al
    Phase II Trial of Induction Chemotherapy for Advanced Sinonasal Squamous Cell Carcinoma.
    Clin Cancer Res. 2025;31:258-265.
    >> Share

  24. HUANG YJ, Rieder J, Tan KV, Tenditnaya A, et al
    Targeting c-MET for Endoscopic Detection of Dysplastic Lesions within Barrett's Esophagus Using EMI-137 Fluorescence Imaging.
    Clin Cancer Res. 2025;31:98-109.
    >> Share

  25. FENGER CARLANDER AL, Jakobsen KK, Todsen T, Paaske N, et al
    Long-term effect and safety of mesenchymal stromal cell therapy for radiation-induced hyposalivation in head and neck cancer survivors: A randomised, phase-2, trial.
    Clin Cancer Res. 2025 Jan 3. doi: 10.1158/1078-0432.CCR-24-2663.
    >> Share

    December 2024
  26. MASON RP
    Tumor Hypoxia: Long Ignored but Now Detectable and Potentially Actionable.
    Clin Cancer Res. 2024;30:5503-5504.
    >> Share

  27. DUBEC MJ, Price J, Berks M, Gaffney J, et al
    Oxygen-Enhanced MRI Detects Incidence, Onset, and Heterogeneity of Radiation-Induced Hypoxia Modification in HPV-Associated Oropharyngeal Cancer.
    Clin Cancer Res. 2024;30:5620-5629.
    >> Share

  28. MICHEL L, Jimeno A, Sukari A, Beck JT, et al
    Sacituzumab Govitecan in Patients With Relapsed/Refractory Advanced Head and Neck Squamous Cell Carcinoma: Results From the Phase 2 TROPiCS-03 Basket Study.
    Clin Cancer Res. 2024 Dec 12. doi: 10.1158/1078-0432.CCR-24-2523.
    >> Share

  29. HANNA GJ, Oakley LB, Shi R, ONeill A, et al
    Duvelisib with docetaxel for patients with anti-PD-1 refractory, recurrent or metastatic head and neck squamous cell carcinoma.
    Clin Cancer Res. 2024 Dec 3. doi: 10.1158/1078-0432.CCR-24-2262.
    >> Share

    November 2024
  30. JOHNSON FM, O'Hara MP, Yapindi L, Jiang P, et al
    Phase 1/2 Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas.
    Clin Cancer Res. 2024 Nov 26. doi: 10.1158/1078-0432.CCR-24-2290.
    >> Share

  31. MASTROLONARDO EV, Nunes KL, Llerena P, Nikitina A, et al
    Response-Adaptive Surgical Timing in neoadjuvant immunotherapy demonstrates enhanced pathologic treatment response in Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2024 Nov 25. doi: 10.1158/1078-0432.CCR-24-0037.
    >> Share

  32. WANG X, Kang X, Zhang R, Xue L, et al
    Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial.
    Clin Cancer Res. 2024;30:5061-5072.
    >> Share

  33. LI Q, Zhang W, Liao T, Gao Y, et al
    An AI-driven preoperative radiomic subtype for predicting the prognosis and treatment response of patients with papillary thyroid carcinoma.
    Clin Cancer Res. 2024 Nov 13. doi: 10.1158/1078-0432.CCR-24-2356.
    >> Share

    October 2024
  34. HANSEN AR, Gomez-Roca CA, Robbrecht DGJ, Verlingue L, et al
    Phase 1b Study of the Immunocytokine Simlukafusp alfa (FAP-IL2v), in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2024 Oct 18. doi: 10.1158/1078-0432.CCR-24-1562.
    >> Share

  35. CHAMSEDDINE I, Shah K, Lee H, Ehret F, et al
    Decoding Patient Heterogeneity Influencing Radiation-Induced Brain Necrosis.
    Clin Cancer Res. 2024;30:4424-4433.
    >> Share

    September 2024
  36. BARRETT AM, Britton ZT, Carrasco RA, Breen S, et al
    Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancer.
    Clin Cancer Res. 2024 Sep 25. doi: 10.1158/1078-0432.CCR-24-1853.
    >> Share

  37. STONE LD, Kasten BB, Rao S, Gonzalez ML, et al
    Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer.
    Clin Cancer Res. 2024;30:4016-4028.
    >> Share

  38. WARNER BE, Patel J, Wang R, Adams-Haduch J, et al
    The Epstein-Barr virus nuclear antigen 1 variant associated with nasopharyngeal carcinoma defines the sequence criteria for serologic risk prediction.
    Clin Cancer Res. 2024 Sep 12. doi: 10.1158/1078-0432.CCR-24-1142.
    >> Share

    August 2024
  39. SABA NF, Chaudhary R, Kirtane K, Marra A, et al
    Pembrolizumab and cabozantinib in recurrent and/or metastatic head and neck squamous cell carcinoma (RMHNSCC): long-term survival update with a biomarker analysis.
    Clin Cancer Res. 2024 Aug 21. doi: 10.1158/1078-0432.CCR-24-1202.
    >> Share

  40. HONMA Y, Monden N, Yamazaki K, Kano S, et al
    Apalutamide and Goserelin for Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU.
    Clin Cancer Res. 2024;30:3416-3427.
    >> Share

    July 2024
  41. FORSTER M, Brana I, Lopez Pousa A, Doger B, et al
    Eftilagimod alpha (soluble LAG-3 protein) combined with pembrolizumab as second-line therapy for patients with metastatic head and neck squamous cell carcinoma.
    Clin Cancer Res. 2024 Jul 12. doi: 10.1158/1078-0432.CCR-24-0473.
    >> Share

    June 2024
  42. FRENCH JD, Haugen BR, Worden FP, Bowles DW, et al
    Combination Targeted Therapy with Lenvatinib and Pembrolizumab in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers.
    Clin Cancer Res. 2024 Jun 26. doi: 10.1158/1078-0432.CCR-23-3417.
    >> Share

  43. HANNA GJ, Dennis MJ, Scarfo N, Mullin MS, et al
    Personalized circulating tumor DNA for monitoring disease status in head and neck squamous cell carcinoma.
    Clin Cancer Res. 2024 Jun 2. doi: 10.1158/1078-0432.CCR-24-0590.
    >> Share

    May 2024
  44. SCHMIDT I, Zhao X, van der Waaij AM, Meersma GJ, et al
    Ultrasound-guided quantitative fluorescence molecular endoscopy for monitoring response in patients with esophageal cancer following neoadjuvant chemoradiotherapy.
    Clin Cancer Res. 2024 May 30. doi: 10.1158/1078-0432.CCR-24-0446.
    >> Share

  45. BALLOUT F, Lu H, Bhat N, Chen L, et al
    Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair.
    Clin Cancer Res. 2024;30:2193-2205.
    >> Share

  46. HANNA GJ, Grover P, Elliott A, McGrath J, et al
    Molecular Profiling and the Impact of Treatment on Outcomes in Adenoid Cystic Carcinoma Type I and II.
    Clin Cancer Res. 2024;30:2225-2232.
    >> Share

  47. PENG X, Zhao H, Ye L, Hou F, et al
    Biomarker identification and risk prediction model development for differentiated thyroid carcinoma lung metastasis based on primary lesion proteomics.
    Clin Cancer Res. 2024 May 9. doi: 10.1158/1078-0432.CCR-23-3806.
    >> Share

  48. TANG T, Zhou Z, Chen M, Li N, et al
    Plasma Metabolic Profiles-Based Prediction of Induction Chemotherapy Efficacy in Nasopharyngeal Carcinoma: Results of a Bidirectional Clinical Trial.
    Clin Cancer Res. 2024 May 7. doi: 10.1158/1078-0432.CCR-23-3608.
    >> Share

  49. PRENEN H, Deva S, Keam B, Lindsay CR, et al
    Phase II study to determine the anti-tumor activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in esophageal cancer.
    Clin Cancer Res. 2024 May 6. doi: 10.1158/1078-0432.CCR-23-2677.
    >> Share

  50. ROSS RB, Gadwa J, Yu J, Darragh LB, et al
    PPARalpha Agonism Enhances Immune Response to Radiotherapy While Dietary Oleic Acid Results in Counteraction.
    Clin Cancer Res. 2024;30:1916-1933.
    >> Share

  51. LIU Y, Yan W, Hu C, Huang X, et al
    Optimizing Cervical Target Volume in Patients with Nasopharyngeal Cancer Based On Nodal Drainage Distance.
    Clin Cancer Res. 2024;30:1801-1810.
    >> Share

    April 2024
  52. SHANNON NB, Iyer NG
    Unveiling Liquid Gold: Lymph as an HPV Marker in OPSCC to Guide Treatment Decisions.
    Clin Cancer Res. 2024;30:1223-1225.
    >> Share

  53. EARLAND N, Semenkovich NP, Ramirez RJ, Gerndt SP, et al
    Sensitive MRD Detection from Lymphatic Fluid after Surgery in HPV-Associated Oropharyngeal Cancer.
    Clin Cancer Res. 2024;30:1409-1421.
    >> Share

  54. READ ML, Brookes K, Zha L, Manivannan S, et al
    Combined Vorinostat and Chloroquine Inhibit Sodium-Iodide Symporter Endocytosis and Enhance Radionuclide Uptake In Vivo.
    Clin Cancer Res. 2024;30:1352-1366.
    >> Share

    March 2024
  55. ZANONI DK, Demetrio De Souza Franca P, Valero C, Peterson G, et al
    A Prospective Double-Blinded Comparison of Reflectance Confocal Microscopy with Conventional Histopathology for In Vivo Assessment in Oral Cancer.
    Clin Cancer Res. 2024 Mar 25. doi: 10.1158/1078-0432.CCR-23-1361.
    >> Share

  56. SWIECICKI PL, Bellile E, Dragovic AF, McHugh J, et al
    Upfront neck dissection for treatment selection and improvement in quality of life as a novel treatment paradigm for deintensification in HPV+ OPSCC.
    Clin Cancer Res. 2024 Mar 22. doi: 10.1158/1078-0432.CCR-23-3247.
    >> Share

  57. KIM CG, Hong MH, Kim D, Lee BH, et al
    A phase II open-label randomized clinical trial of preoperative durvalumab or durvalumab plus tremelimumab in resectable head and neck squamous cell carcinoma.
    Clin Cancer Res. 2024 Mar 8. doi: 10.1158/1078-0432.CCR-23-3249.
    >> Share

  58. JAKOBSEN K, Carlander AF, Todsen T, Melchiors J, et al
    Mesenchymal Stem/Stromal Cell Therapy for Radiation-Induced Xerostomia in Previous Head and Neck Cancer Patients: A Phase 2 Randomised, Placebo-Controlled Trial.
    Clin Cancer Res. 2024 Mar 5. doi: 10.1158/1078-0432.CCR-23-3675.
    >> Share

    February 2024
  59. SAITO S, Kono M, Nguyen HCB, Egloff AM, et al
    Targeting Dendritic Cell Dysfunction to Circumvent anti-PD1 Resistance in Head and Neck Cancer.
    Clin Cancer Res. 2024 Feb 19. doi: 10.1158/1078-0432.CCR-23-3477.
    >> Share

    January 2024
  60. MEHANNA H, Rapozo D, von Zeidler SV, Harrington KJ, et al
    Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study.
    Clin Cancer Res. 2024;30:356-367.
    >> Share

  61. LECHNER MG, Brent GA
    A New Twist on a Classic: Enhancing Radioiodine Uptake in Advanced Thyroid Cancer.
    Clin Cancer Res. 2024 Jan 10. doi: 10.1158/1078-0432.CCR-23-3503.
    >> Share

  62. VON WITZLEBEN A, Ellis M, Thomas GJ, Hoffmann TK, et al
    Tumor-Infiltrating CD103+ Tissue-Resident Memory T Cells and CD103-CD8+ T Cells in HNSCC Are Linked to Outcome in Primary but not Metastatic Disease.
    Clin Cancer Res. 2024;30:224-234.
    >> Share

  63. PENA-OYARZUN D, Flores T, Torres VA, Quest AFG, et al
    Inhibition of PORCN Blocks Wnt Signaling to Attenuate Progression of Oral Carcinogenesis.
    Clin Cancer Res. 2024;30:209-223.
    >> Share

    December 2023
  64. KIM YH, Yoon SJ, Kim M, Kim HH, et al
    Integrative multi-omics analysis reveals different metabolic phenotypes based on molecular characteristics in thyroid cancer.
    Clin Cancer Res. 2023 Dec 13. doi: 10.1158/1078-0432.CCR-23-2025.
    >> Share

    November 2023
  65. NGAMPHAIBOON N, Pattaranutaporn P, Lukerak S, Siripoon T, et al
    A Phase I Study of the CDK4/6 Inhibitor, Palbociclib in Combination with Cetuximab and Radiotherapy (IMRT) for Locally Advanced Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2023 Nov 20. doi: 10.1158/1078-0432.CCR-23-2303.
    >> Share

  66. OU X, Zhai R, Wei W, Chen J, et al
    Induction Toripalimab And Chemotherapy For Organ Preservation In Locally Advanced Laryngeal And Hypopharyngeal Cancer: A Single-Arm Phase 2 Clinical Trial.
    Clin Cancer Res. 2023 Nov 13. doi: 10.1158/1078-0432.CCR-23-2398.
    >> Share

  67. SHEN C, Shi X, Wen D, Zhang Y, et al
    Comprehensive DNA Methylation Profiling of Medullary Thyroid Carcinoma: Molecular Classification, Potential Therapeutic Target, and Classifier System.
    Clin Cancer Res. 2023 Nov 6. doi: 10.1158/1078-0432.CCR-23-2142.
    >> Share

    October 2023
  68. HANNA GJ, Roof SA, Jabalee J, Rettig EM, et al
    Negative Predictive Value of Circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA for HPV-driven Oropharyngeal Cancer Surveillance.
    Clin Cancer Res. 2023;29:4306-4313.
    >> Share

  69. PIFER PM, Yang L, Kumar M, Xie T, et al
    FAK drives resistance to therapy in HPV-negative head and neck cancer in a p53-dependent manner.
    Clin Cancer Res. 2023 Oct 11. doi: 10.1158/1078-0432.CCR-23-0964.
    >> Share

  70. FU H, Huang J, Zhao T, Wang H, et al
    Fibroblast Activation Protein-Targeted Radioligand Therapy with 177Lu-EB-FAPI for Metastatic Radioiodine Refractory Thyroid Cancer: First-in-Human, Dose-Escalation Study.
    Clin Cancer Res. 2023 Oct 6. doi: 10.1158/1078-0432.CCR-23-1983.
    >> Share

  71. KLEMPNER SJ, Lee KW, Shitara K, Metges JP, et al
    ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
    Clin Cancer Res. 2023;29:3882-3891.
    >> Share

  72. JAKOBSEN KK, Bendtsen SK, Pallisgaard N, Friborg J, et al
    Liquid Biopsies with Circulating Plasma HPV-DNA Measurements-A Clinically Applicable Surveillance Tool for Patients with HPV-Positive Oropharyngeal Cancer.
    Clin Cancer Res. 2023;29:3914-3923.
    >> Share

    September 2023
  73. DERRY JMJ, Burns C, Frazier JP, Beirne E, et al
    Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment.
    Clin Cancer Res. 2023;29:3813-3825.
    >> Share

  74. DUKE ES, Bradford D, Marcovitz M, Amatya AK, et al
    FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors.
    Clin Cancer Res. 2023;29:3573-3578.
    >> Share

  75. LEE MS, Kaseb AO, Pant S
    The Emerging Role of Circulating Tumor DNA in Non-Colorectal Gastrointestinal Cancers.
    Clin Cancer Res. 2023;29:3267-3274.
    >> Share

    August 2023
  76. NIU Z, Sun P, Liu H, Wei P, et al
    Functional Genetic Variants in TGFbeta1 and TGFbetaR1 in miRNA-Binding Sites Predict Outcomes in Patients with HPV-positive Oropharyngeal Squamous Cell Carcinoma.
    Clin Cancer Res. 2023;29:3081-3091.
    >> Share

    June 2023
  77. HU H, Ng TSC, Kang M, Scott E, et al
    Thyroid cancers exhibit oncogene-enhanced macropinocytosis that is restrained by IGF1R and promotes albumin-drug-conjugate response.
    Clin Cancer Res. 2023 Jun 8:CCR-22-2976. doi: 10.1158/1078-0432.CCR-22-2976.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016